Albuquerque, NM, 10 January, 2022 – Indica Labs, a leading provider of computational pathology software and services, is proud to announce that following ISO13485 certification, HALO AP® has received a CE Mark for use in primary diagnosis within the European Economic Area, Switzerland, and the UK.
At Indica Labs, our Pharma Services team is here to help you extract more data from your biomarker assays with our digital image analysis services. From single biomarker IHC to ISH/FISH and highly multiplexed fluorescence and imaging mass cytometry, we offer quantitative image analysis solutions with our own HALO and HALO AI analysis platforms. With over 150 completed image analysis projects, our team has experience across multiple disease areas, applications, and assay types, including immune phenotyping in tumors, biomarker expression profiling across TMAs and whole slide tissues, pharmacodynamic assays, target validation studies, and more. In addition to leveraging our own image analysis and image management solutions, we utilize the in-house expertise of our image analysts and algorithm development teams to enable you to make the right decisions about your biomarker program.
Bridge the Gap with Indica Labs’ Pharma Services Read More »
Expansive Interview Vlado Ovtcharov: Senior Research Scientist – Artificial Intelligence
An Interview with Vlado Ovtcharov, Senior Research Scientist – Artificial Intelligence Read More »
As 2021 draws to a close, the team at Indica Labs would like to take this opportunity to reflect on the year and to thank our customers for their continued support through this second pandemic year. Despite the ongoing challenges that the pandemic presents, we celebrate the achievements of our customers who have published over 250 publications in peer-reviewed journals this year with an impressive average impact factor of 9.12. To learn more about these publications spanning immuno-oncology, oncology, immunology, infectious disease, and neurology, read our high-impact publications guide and visit our Literature page.
2021: A Year in Review at Indica Labs Read More »
20 January 2022 | In this 60-minute webinar, learn how HALO and HALO AI collaborate to perform tissue and cell segmentation, quantification of T-cell subsets in tumor regions, and spatial analysis .
13 January 2022 | In this 60-minute webinar, researchers and pathologists from the University of New Mexico will discuss their recently published study using the HALO AI deep learning convolutional neural network (CNN) to determine whether a CNN can differentiate autoimmune gastritis from Helicobacter pylori gastritis.
16 December 2021 | In this Masterclass webinar we will delve into one of the latest AI tools, the AI validation workflow (available as of the HALO v3.3 release). This tool can be used to answer the question How good is my trained AI network?
2021 Masterclass: HALO AI Deep Dive on the Validation Workflow Read More »
10 December 2021 | In this 1-hour webinar, featured speakers will demonstrate end-to-end how to develop a quantitative assay in HALO and transition it into clinical trials using HALO AP.
Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP® Read More »
03 December 2021 | In this webinar you will learn how the Pharma Services team at Indica Labs uses HALO Link to collaborate with customers, to launch and display image analysis results, and to archive studies
04 November 2021 | Following up on our HALO 3.2 Masterclass: Deep Dive into AI-based Nuclear Segmentation and Phenotyping, in this Masterclass webinar with HALO 3.3, we will further delve into options for AI-based nuclear segmentation and phenotyping.
2021 Masterclass: Deep Dive into AI-Based Nuclear Segmentation and Phenotyping Part II Read More »
